Secukinumab

RED:

NICE TA350: for treating moderate to severe plaque psoriasis. (Decision date - August 2015)
NICE TA407: for active ankylosing spondylitis after treatment with non steroidal anti-inflammatory drugs or TNF-alpha inhibitors. (Decision date - October 2016)
NICE TA445: Certolizumab and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. (Decision date - June 2017)
NICE TA719: secukinumab for treating non-radiographic axial spondyloarthritis. (Decision date - August 2021)
NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NHSE commissioned (Decision date - Nov 2021)
NICE TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa. NHSE commissioned. (Decision date - January 2024)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)